GC Aesthetics Ltd announces the results of an independent clinical study documenting the safety and patient satisfaction results for the company’s breast implants, based upon an average of 17 years of patient follow-up.

The study, led by Prof van der Lei in The Netherlands (Kooiman et al. 2021), analyzed the very long-term patient satisfaction and exceptionally low revision rate for GCA round micro-textured breast implants. It also reported no ALCL (Anaplastic Large Cell Lymphoma) cases from GCA implants.

In breast augmentation surgery with implants, it has been seen that the cumulative risk of complications, such as capsular contracture, increases over time. Having significant long-term clinical data regarding the safety of GCA’s breast implants adds important information to the scientific literature, and it also provides powerful evidence of the long-term safety of GC Aesthetics’ breast implants.

“The proven and long-standing safety record of GCA’s products has enabled us to build market-leading positions in key markets around the world, and to earn the confidence of surgeons and patients across the globe. Results like this have allowed GCA to ensure that our products are safe and highly effective in achieving the needs of the industry.

“This clinical study by Prof. Dr. Berend van der Lei, provides evidence of what we have professed for years: long-term data matters, and great long-term results for patients matters even more. Most breast implants in the market are not backed by this kind of data.”

— Carlos Reis Pinto, CEO of GC Aesthetics

GCA has aggressive growth planned for 2022, fueled by its innovative product launches, and its further expansion in key markets, capitalizing on its success in 2021, the company notes in a media release.

[Source(s): GC Aesthetics Ltd, Business Wire]